| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More | Frank Vinluan | 12/14/18 | National |
| Kodiak Sciences Files for IPO to Fund Global AMD Eye-Drug Studies | Frank Vinluan | 09/10/18 | San Francisco |
| For More Lung Cancer Patients, the Promise of No Chemo Looms Larger | Alex Lash | 04/16/18 | National |
| Merck Is Latest to Tout Success as Lung Cancer Drug Combos Plow Forward | Ben Fidler | 01/16/18 | New York |
| Bio Roundup: Trials to Watch, Mega Deals, Video Game Therapy & More | Ben Fidler | 12/08/17 | Boston |
| Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More | Frank Vinluan | 12/01/17 | National |
| Lacking Details, Roche Touts Drug Combo’s Success in Lung Cancer | Ben Fidler | 11/20/17 | San Francisco |
| Gemini Reels In $42M to Target Root Causes of Age-Related Blindness | Frank Vinluan | 10/17/17 | Boston |
| Bio Roundup: Phase 3 Fails, Shkreli Jailed, Moderna Flip-Flops & More | Alex Lash | 09/15/17 | National |
| Ophthotech’s Final Try at Combo Eye Drug Comes up Short | Ben Fidler | 08/14/17 | New York |
| Waving White Flag, Cerulean Merges With Dare Bio, Sells Cancer Drugs | Ben Fidler | 03/20/17 | Boston |
| Another Notch For “PARP” Blockers As FDA Approves Clovis Cancer Drug | Ben Fidler | 12/19/16 | Boulder/Denver |
| After Setback, Ophthotech Restructures, Dials Down Eye Drug Studies | Ben Fidler | 12/16/16 | New York |
| Ophthotech Eye Drug Fails Badly in Pivotal Test, Shares Crumble | Ben Fidler | 12/12/16 | New York |
| On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data | Ben Fidler | 11/01/16 | National |
| Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA | Ben Fidler | 08/26/16 | National |
| Cerulean’s Shares Routed as Cancer Drug Comes up Short Again | Ben Fidler | 08/17/16 | Boston |
| American Copycats: Can Biosimilars Catch On And Cut Costs In U.S.? | Alex Lash | 09/15/15 | National |
| East Coast Biotech Roundup: Regeneron, Synergy, Foundation & More | Ben Fidler | 07/31/15 | Boston |
| The Near Death, and Second Life, of Cerulean Pharma | Ben Fidler | 07/13/15 | Boston |
| Celldex Builds Case for Brain Cancer Vaccine With New ASCO Data | Ben Fidler | 05/31/15 | New York |
| West Coast Biotech Roundup: Laguna, SeaGen, Unchained, DME & More | Alex Lash | 02/19/15 | San Francisco |
| Celldex Touts Brain Cancer Vaccine Data, Talks FDA Strategy | Ben Fidler | 11/14/14 | New York |
| Military Strategies Being Used in the War on Cancer | Stewart Lyman | 08/04/14 | Seattle |
| Avalanche Bio Rolls Onto Nasdaq After Upsized, $102M IPO | Ben Fidler | 07/31/14 | San Francisco |
| East Coast Biotech Roundup: Bristol, PTC, Ophthotech, & More | Ben Fidler | 05/27/14 | Boston |
| Ophthotech, Novartis Team up on $1B Deal for Eye Drug | Ben Fidler | 05/19/14 | New York |
| Kala Pharma Grabs $22.5M More For Eye Drugs | Ben Fidler | 04/23/14 | Boston |
| Cerulean Limps into Nasdaq Debut With $7 Per Share IPO | Ben Fidler | 04/10/14 | Boston |
